DK3139963T3 - Konjugater og prodrugs til behandling af cancer og inflammatoriske sygdomme - Google Patents

Konjugater og prodrugs til behandling af cancer og inflammatoriske sygdomme Download PDF

Info

Publication number
DK3139963T3
DK3139963T3 DK15709742.9T DK15709742T DK3139963T3 DK 3139963 T3 DK3139963 T3 DK 3139963T3 DK 15709742 T DK15709742 T DK 15709742T DK 3139963 T3 DK3139963 T3 DK 3139963T3
Authority
DK
Denmark
Prior art keywords
prodrugs
conjugates
cancer
treatment
inflammatory diseases
Prior art date
Application number
DK15709742.9T
Other languages
English (en)
Inventor
Sébastien Papot
Isabelle Opalinski
Brigitte Renoux
Thibaut Legigan
Original Assignee
Centre Nat Rech Scient
Univ Poitiers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Univ Poitiers filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of DK3139963T3 publication Critical patent/DK3139963T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK15709742.9T 2014-02-07 2015-02-06 Konjugater og prodrugs til behandling af cancer og inflammatoriske sygdomme DK3139963T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1450956A FR3017298B1 (fr) 2014-02-07 2014-02-07 Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires
PCT/IB2015/050914 WO2015118497A1 (fr) 2014-02-07 2015-02-06 Conjugués et pro-drogues pour le traitement du cancer et de maladies inflammatoires

Publications (1)

Publication Number Publication Date
DK3139963T3 true DK3139963T3 (da) 2020-10-26

Family

ID=50829100

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15709742.9T DK3139963T3 (da) 2014-02-07 2015-02-06 Konjugater og prodrugs til behandling af cancer og inflammatoriske sygdomme

Country Status (9)

Country Link
US (1) US10293021B2 (da)
EP (2) EP3139963B1 (da)
JP (1) JP6721512B2 (da)
CN (2) CN114917358A (da)
CA (1) CA2938501C (da)
DK (1) DK3139963T3 (da)
ES (1) ES2843798T3 (da)
FR (1) FR3017298B1 (da)
WO (1) WO2015118497A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10722593B2 (en) 2015-10-02 2020-07-28 Sirenas Llc Anti-cancer compounds and conjugates thereof
ES2948846T3 (es) * 2016-03-29 2023-09-20 Toray Industries Derivado peptídico y uso del mismo
EP3624854A1 (en) 2017-05-16 2020-03-25 Université de Strasbourg Protein-drug conjugates and their use in the treatment of cancers
MX2020005658A (es) * 2017-11-30 2020-11-11 Centurion Biopharma Corp Profarmacos de union a albumina de derivados de auristatina e.
WO2019192979A1 (en) 2018-04-03 2019-10-10 Syndivia Conjugate of cytotoxic drug and prodrug form of said conjugate
AU2020268749A1 (en) * 2019-05-06 2021-12-02 Centre National De La Recherche Scientifique New therapeutic vectors and prodrugs for treating cancers
FR3126982B1 (fr) * 2021-09-14 2023-09-15 Centre Nat Rech Scient Vecteurs ciblant la beta-d-n-acetylglucosaminidase
CN116077674A (zh) * 2022-12-26 2023-05-09 北京大学 生物分子-聚氮氧化物偶联物及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
CA2616005C (en) * 2005-07-18 2015-09-22 Seattle Genetics, Inc. Beta-glucuronide-linker drug conjugates
FR2960153B1 (fr) 2010-05-20 2012-08-17 Centre Nat Rech Scient Nouveaux bras autoreactifs et prodrogues les comprenant

Also Published As

Publication number Publication date
JP6721512B2 (ja) 2020-07-15
EP3766510A1 (fr) 2021-01-20
WO2015118497A1 (fr) 2015-08-13
US10293021B2 (en) 2019-05-21
CA2938501A1 (fr) 2015-08-13
EP3139963A1 (fr) 2017-03-15
FR3017298B1 (fr) 2016-03-04
ES2843798T3 (es) 2021-07-20
FR3017298A1 (fr) 2015-08-14
US20170095525A1 (en) 2017-04-06
JP2017506628A (ja) 2017-03-09
CN114917358A (zh) 2022-08-19
EP3139963B1 (fr) 2020-10-07
CA2938501C (fr) 2022-04-05
CN106573071A (zh) 2017-04-19

Similar Documents

Publication Publication Date Title
DK3288581T3 (da) Fremgangsmåde til behandling af cancer
DK3189082T3 (da) Anti-pd-l1-konjugater til behandling af tumorer
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
DK3319993T3 (da) AXL-SPECIFIKKE antistof-lægemiddelkonjugater til kræftbehandling
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3155024T3 (da) Opholdsstrukturer og relaterede fremgangsmåder
DK3119797T3 (da) Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
DK3033086T3 (da) Kombinationsterapi til behandling af cancer
DK3137114T3 (da) Anti-PTK7-antistof-lægemiddelkonjugater
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
BR112017011771A2 (pt) métodos e composições para o tratamento de câncer
DK3169328T3 (da) Quinolinderivater til behandling af inflammationssygdomme
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
KR20180084772A (ko) 암 치료를 위한 조합 치료법
BR112016027041A2 (pt) Combinações farmacêuticas para tratamento do câncer
DK3622953T3 (da) Kombinationsbehandling af cancer
DK3200815T3 (da) Fremgangsmåder og sammensætninger til behandling af cancer
DK3139963T3 (da) Konjugater og prodrugs til behandling af cancer og inflammatoriske sygdomme
MA39483A (fr) Agents thérapeutiques cibles
DK3186244T3 (da) Dioxolananaloger af uridin til behandling af cancer
DK3189074T3 (da) Sammensætninger og metoder til behandling og forebyggelse af inflammation
DK3110446T3 (da) Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme